CONCORDBIO vs HALEOSLABS: Stock Comparison

Concord Biotech Limited vs Haleos Labs Limited

Live data: 22 July 2026, 3:05 PM IST • Source: NSE and company filings

Concord Biotech Limited is the larger company by market capitalisation. Concord Biotech Limited shows a higher ROE, a higher dividend yield and lower leverage, while Haleos Labs Limited shows a lower P/E and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Concord Biotech Limited and Haleos Labs Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, CONCORDBIO is more favourable on 7 of 13 scored metrics and HALEOSLABS on 6These counts are context-free and are not an overall rating.

Key Differences

Market Cap
CONCORDBIO is the larger company
₹13,477 Cr vs ₹484 Cr
P/E Ratio
HALEOSLABS has a lower P/E
27.94x vs 53.3x
P/B Ratio
HALEOSLABS has a lower P/B
2.27x vs 6.89x
EPS
HALEOSLABS has higher earnings per share
₹57.3 vs ₹24.83
Dividend Yield
CONCORDBIO has a higher dividend yield
0.57% vs 0.1%
Revenue Growth (TTM YoY)
HALEOSLABS has faster revenue growth
0% vs -24.1%
EPS Growth (TTM YoY)
HALEOSLABS has faster EPS growth
0% vs -37%
Qtr Sales Growth
HALEOSLABS has stronger quarterly sales growth
-15.7% vs -24.2%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricCONCORDBIOHALEOSLABS
SectorHealthcare
IndustryPharmaceuticals

Price

MetricCONCORDBIOHALEOSLABS
Live Price₹1,286.2₹1,522.4
Day Change-3.24%-3.09%
Volume76,894281
52-Week High₹1,980₹1,774
52-Week Low₹987₹1,181
Distance from 52W High-35.04%-14.18%

Valuation

MetricCONCORDBIOHALEOSLABS
Market Cap₹13,477 Cr₹484 Cr
P/E Ratio53.3x27.94x
P/B Ratio6.89x2.27x
EPS₹24.83₹57.3
Book Value₹192.81₹706
Dividend Yield0.57%0.1%

Growth

MetricCONCORDBIOHALEOSLABS
Revenue Growth (TTM YoY)-24.1%0%
EPS Growth (TTM YoY)-37%0%
Qtr Sales Growth-24.2%-15.7%
Qtr Profit Growth-36.8%-85.2%

Profitability & Leverage

MetricCONCORDBIOHALEOSLABS
ROE13.8%8.44%
ROCE18.2%9.91%
Net Margin24.6%5.33%
Operating Margin34.8%13.4%
Debt to Equity0x0.52x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricCONCORDBIOHALEOSLABS
Promoter Holding44.08%72.11%
FII Holding7.8% 0.22 pp0%
DII Holding9.22% 0.36 pp0.31% 0.01 pp
Public Holding38.9% 0.14 pp27.58% 0.02 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Concord Biotech Limited and Haleos Labs Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.